Inhibiting CDK4/6 in breast cancer with palbociclib, ribociclib, and abemaciclib: similarities and differences
CL Braal, EM Jongbloed, SM Wilting, RHJ Mathijssen… - Drugs, 2021 - Springer
The cyclin-dependent kinase (CDK) 4/6 inhibitors belong to a new class of drugs that
interrupt proliferation of malignant cells by inhibiting progression through the cell cycle …
interrupt proliferation of malignant cells by inhibiting progression through the cell cycle …
Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review …
M Giuliano, F Schettini, C Rognoni, M Milani… - The Lancet …, 2019 - thelancet.com
Background Although international guidelines support the administration of hormone
therapies with or without targeted therapies in postmenopausal women with hormone …
therapies with or without targeted therapies in postmenopausal women with hormone …
Endocrine treatment and targeted therapy for hormone receptor–positive, human epidermal growth factor receptor 2–negative metastatic breast cancer: ASCO …
HJ Burstein, MR Somerfield, DL Barton… - Journal of clinical …, 2021 - ascopubs.org
PURPOSE To update recommendations of the ASCO systemic therapy for hormone receptor
(HR)-positive metastatic breast cancer (MBC) guideline. METHODS An Expert Panel …
(HR)-positive metastatic breast cancer (MBC) guideline. METHODS An Expert Panel …
Rationale and trial design of NATALEE: a Phase III trial of adjuvant ribociclib + endocrine therapy versus endocrine therapy alone in patients with HR+/HER2− early …
DJ Slamon, PA Fasching, S Hurvitz… - Therapeutic …, 2023 - journals.sagepub.com
Background: Ribociclib has demonstrated a statistically significant overall survival benefit in
pre-and postmenopausal patients with hormone receptor positive/human epidermal growth …
pre-and postmenopausal patients with hormone receptor positive/human epidermal growth …
Are all cyclin-dependent kinases 4/6 inhibitors created equal?
A Marra, G Curigliano - NPJ breast cancer, 2019 - nature.com
The harnessing in clinical practice of cyclin-dependent kinases 4/6 inhibitors, namely
palbociclib, ribociclib, and abemaciclib, has substantially changed the therapeutic approach …
palbociclib, ribociclib, and abemaciclib, has substantially changed the therapeutic approach …
Endocrine treatment for breast cancer patients revisited—history, standard of care, and possibilities of improvement
N Nabieva, PA Fasching - Cancers, 2021 - mdpi.com
Simple Summary Tamoxifen, aromatase inhibitors, and fulvestrant are the main drugs that
have been used for decades in the treatment of patients with endocrine-therapy-sensitive …
have been used for decades in the treatment of patients with endocrine-therapy-sensitive …
Health-related quality of life in premenopausal women with hormone-receptor-positive, HER2-negative advanced breast cancer treated with ribociclib plus endocrine …
N Harbeck, F Franke… - Therapeutic …, 2020 - journals.sagepub.com
Background: This analysis evaluated patient-reported outcomes (PROs) to assess health-
related quality of life (HRQoL) in the phase III MONALEESA-7 trial, which previously …
related quality of life (HRQoL) in the phase III MONALEESA-7 trial, which previously …
Comparative efficacy of palbociclib, ribociclib and abemaciclib for ER+ metastatic breast cancer: an adjusted indirect analysis of randomized controlled trials
F Petrelli, A Ghidini, R Pedersini, M Cabiddu… - Breast cancer research …, 2019 - Springer
Background Several trials have demonstrated the benefit of anti-CDK4/6 inhibitors plus
endocrine therapy in estrogen receptor-positive (ER+) advanced breast cancer (BC), in first …
endocrine therapy in estrogen receptor-positive (ER+) advanced breast cancer (BC), in first …
Health‐related quality of life in MONARCH 2: Abemaciclib plus fulvestrant in hormone receptor‐positive, HER2‐negative advanced breast cancer after endocrine …
PA Kaufman, M Toi, P Neven, J Sohn… - The …, 2020 - academic.oup.com
Background In the phase III MONARCH 2 study (NCT02107703), abemaciclib plus
fulvestrant significantly improved progression‐free survival (PFS) versus placebo plus …
fulvestrant significantly improved progression‐free survival (PFS) versus placebo plus …
[HTML][HTML] Health-related quality of life in breast cancer patients treated with CDK4/6 inhibitors: a systematic review
V Di Lauro, G Barchiesi, F Martorana, G Zucchini… - ESMO open, 2022 - Elsevier
Background Evaluation of health-related quality of life (HR-QoL) among cancer patients has
gained an increasing importance and is now a key determinant of anticancer treatments' …
gained an increasing importance and is now a key determinant of anticancer treatments' …